Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease

Intrabodies offer attractive options for manipulating the protein misfolding that triggers neurodegenerative diseases. In Huntington's disease, where the expanded polyglutamine tract in the extreme N-terminal region of huntingtin exon1 misfolds, two lead intrabodies have been selected against a...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler, D.C., Snyder-Keller, A., De Genst, E., Messer, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Creativity Engenders Next-Generation Antibody Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191446/
https://www.ncbi.nlm.nih.gov/pubmed/25301961
http://dx.doi.org/10.1093/protein/gzu041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191446/
https://www.ncbi.nlm.nih.gov/pubmed/25301961
http://dx.doi.org/10.1093/protein/gzu041

Ejemplares similares